Brain imaging after neural transplantation

Progress in Brain Research

Volumn 184, Issue C, 2010, Pages 193-203

  Politis, Marios ^a   Piccini, Paola ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Neural grafts; Parkinson; PET; SPECT

Indexed keywords

6 FLUORODOPA F 18;

BOOK; BRAIN METABOLISM; CELL MATURATION; CELL THERAPY; CLINICAL OBSERVATION; CLINICAL TRIAL; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DYSKINESIA; GRAFT SURVIVAL; HUMAN; INFLAMMATION; NERVE GRAFT; NEUROIMAGING; NONHUMAN; PARKINSON DISEASE; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

EID: 77957237620     PISSN: 00796123     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6123(10)84010-5     Document Type: Chapter

References (71)

1. Antonini A., Schwarz J., Oertel W.H., Beer H.F., Madeja U.D., Leenders K.L. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors. Neurology 1994, 44:1325-1329.
2. Brooks D.J. Positron emission tomography imaging of transplant function. NeuroRx 2004, 1:482-491.
3. Brooks D.J., Ibanez V., Sawle G.V., Playford E.D., Quinn N., Mathias C.J., et al. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C-raclopride and positron emission tomography. Annals of Neurology 1992, 31:184-192.
4. Brundin P., Pogarell O., Hagell P., Piccini P., Widner H., Schrag A., et al. Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. Brain 2000, 123:1380-1390.
5. Ceballos-Baumann A.O., Boecker H., Bartenstein P., von Falkenhayn I., Riescher H., Conrad B., et al. A positron emission tomographic study of subthalamic nucleus stimulation in Parkinson disease: Enhanced movement-related activity of motor-association cortex and decreased motor cortex resting activity. Archives of Neurology 1999, 56:997-1003.
6. Chugani D.C., Ackermann R.F., Phelps M.E. In vivo [3H]spiperone binding: evidence for accumulation in corpus striatum by agonist-mediated receptor internalization. Journal of Cerebral Blood Flow and Metabolism 1988, 8:291-303.
7. Ciccarelli O., Catani M., Johansen-Berg H., Clark C., Thompson A. Diffusion-based tractography in neurological disorders: Concepts, applications, and future developments. Lancet Neurology 2008, 7:715-727.
8. Cochen V., Ribeiro M.J., Nguyen J.P., Gurruchaga J.M., Villafane G., Loc'h C., et al. Transplantation in Parkinson's disease: PET changes correlate with the amount of grafted tissue. Movement Disorder 2003, 18:928-932.
9. de la Fuente-Fernández R., Lu J.Q., Sossi V., Jivan S., Schulzer M., Holden J.E., et al. Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover. Annals of Neurology 2001, 49:298-303.
10. Defer G.L., Geny C., Ricolfi F., Fenelon G., Monfort J.C., Remy P., et al. Long-term outcome of unilaterally transplanted parkinsonian patients. I. Clinical approach. Brain 1996, 119:41-50.
11. Eidelberg D., Moeller J.R., Dhawan V., Spetsieris P., Takikawa S., Ishikawa T., et al. The metabolic topography of parkinsonism. Journal of Cerebral Blood Flow and Metabolism 1994, 14:783-801.
12. Eidelberg D., Moeller J.R., Ishikawa T., Dhawan V., Spetsieris P., Chaly T., et al. Assessment of disease severity in parkinsonism with fluorine-18-fluorodeoxyglucose and PET. Journal of Nuclear. Medicine 1995, 36:378-383.
13. Firnau G., Sood S., Chirakal R., Nahmias C., Garnett E.S. Cerebral metabolism of 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine in the primate. Journal of Neurochemistry 1987, 48:1077-1082.
14. Freed C.R., Breeze R.E., Rosenberg N.L., Schneck S.A., Kriek E., Qi J.X., et al. Survival of implanted fetal dopamine cells and neurologic improvement 12 to 46 months after transplantation for Parkinson's disease. New England Journal of Medicine 1992, 327:1549-1555.
15. Freed C.R., Greene P.E., Breeze R.E., Tsai W.Y., DuMouchel W., Kao R., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. New England Journal of Medicine 2001, 344:710-719.
16. Freeman T.B., Olanow C.W., Hauser R.A., Nauert G.M., Smith D.A., Borlongan C.V., et al. Bilateral fetal nigral transplantation into the postcommissural putamen in Parkinson's disease. Annals of Neurology 1995, 38:379-388.
17. Fukuda M., Mentis M., Ghilardi M.F., Dhawan V., Antonini A., Hammerstad J., et al. Functional correlates of pallidal stimulation for Parkinson's disease. Annals of Neurology 2001, 49:155-164.
18. Goerendt I.K., Messa C., Lawrence A.D., Grasby P.M., Piccini P., Brooks D.J. Dopamine release during sequential finger movements in health and Parkinson's disease: A PET study. Brain 2003, 126:312-325.
19. Guye M., Bartolomei F., Ranjeva J.P. Imaging structural and functional connectivity: Towards a unified definition of human brain organization?. Current Opinion in Neurology 2008, 21:393-403.
20. Hagell P., Cenci M.A. Dyskinesias and dopamine cell replacement in Parkinson's disease: A clinical perspective. Brain Research Bulletin 2005, 68:4-15.
21. Hagell P., Piccini P., Björklund A., Brundin P., Rehncrona S., Widner H., et al. Dyskinesias following neural transplantation in Parkinson's disease. Nature Neuroscience 2002, 5:627-628.
22. Hagell P., Schrag A., Piccini P., Jahanshahi M., Brown R., Rehncrona S., et al. Sequential bilateral transplantation in Parkinson's disease: Effects of the second graft. Brain 1999, 122:1121-1132.
23. Hauser R.A., Freeman T.B., Snow B.J., Nauert M., Gauger L., Kordower J.H., et al. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson disease. Archives of Neurology 1999, 56:179-187.
24. Hirano S., Asanuma K., Ma Y., Tang C., Feigin A., Dhawan V., et al. Dissociation of metabolic and neurovascular responses to levodopa in the treatment of Parkinson's disease. Journal of Neuroscience 2008, 28:4201-4209.
25. Huang Z., de la Fuente-Fernandez R., Hauser R.A. Dopaminergic alteration in Parkinson's patients with "off period" dyskinesia following striatal embryonic mesencephalic transplant. Neurology 2003, 60:A126.
26. Huang C., Mattis P., Perrine K., Brown N., Dhawan V., Eidelberg D. Metabolic abnormalities associated with mild cognitive impairment in Parkinson disease. Neurology 2008, 70:1470-1477.
27. Isacson O., Bjorklund L.M., Schumacher J.M. Toward full restoration of synaptic and terminal function of the dopaminergic system in Parkinson's disease by stem cells. Annals of Neurology 2003, 53:S135-S148.
28. Jahanshahi M., Jenkins I.H., Brown R.G., Marsden C.D., Passingham R.E., Brooks D.J. Self-initiated versus externally triggered movements. I. An investigation using measurement of regional cerebral blood flow with PET and movement-related potentials in normal and Parkinson's disease subjects. Brain 1995, 118:913-933.
29. Jenkins I.H., Fernandez W., Playford E.D., Lees A.J., Frackowiak R.S., Passingham R.E., et al. Impaired activation of the supplementary motor area in Parkinson's disease is reversed when akinesia is treated with apomorphine. Annals of Neurology 1992, 32:749-757.
30. Kordower J.H., Chu Y., Hauser R.A., Freeman T.B., Olanow C.W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nature. Medicine 2008, 14:504-506.
31. Kordower J.H., Freeman T.B., Chen E.Y., Mufson E.J., Sanberg P.R., Hauser R.A., et al. Fetal nigral grafts survive and mediate clinical benefit in a patient with Parkinson's disease. Movement Disorder 1998, 13:383-393.
32. Kordower J.H., Freeman T.B., Snow B.J., Vingerhoets F.J., Mufson E.J., Sanberg P.R., et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. New England Journal of Medicine 1995, 332:1118-1124.
33. Kordower J.H., Rosenstein J.M., Collier T.J., Burke M.A., Chen E.Y., Li J.M., et al. Functional fetal nigral grafts in a patient with Parkinson's disease: Chemoanatomic, ultrastructural, and metabolic studies. Journal of Comparative Neurology 1996, 370:203-230.
34. Laruelle M., Abi-Dargham A., van Dyck C.H., Rosenblatt W., Zea-Ponce Y., Zoghbi S.S., et al. SPECT imaging of striatal dopamine release after amphetamine challenge. Journal of Nuclear Medicine 1995, 36:1182-1190.
35. Lindvall O. Cerebral implantation in movement disorders: State of the art. Movement Disorder 1999, 14:201-205.
36. Lindvall O., Björklund A. Cell therapy in Parkinson's disease. NeuroRx 2004, 1:382-393.
37. Lindvall O., Brundin P., Widner H., Rehncrona S., Gustavii B., Frackowiak R., et al. Grafts of fetal dopamine neurons survive and improve motor function in Parkinson's disease. Science 1990, 4942:574-577.
38. Lindvall O., Hagell P. Clinical observations after neural transplantation in Parkinson's disease. Progress in Brain Research 2000, 127:299-320.
39. Lindvall O., Sawle G., Widner H., Rothwell J.C., Björklund A., Brooks D., Brundin P., et al. Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Annals of Neurology 1994, 35:172-180.
40. Ma Y., Feigin A., Dhawan V., Fukuda M., Shi Q., Greene P., et al. Dyskinesia after fetal cell transplantation for parkinsonism: A PET study. Annals of Neurology 2002, 52:628-634.
41. Ma Y., Tang C., Chaly T., Greene P., Breeze R., Fahn S., et al. Dopamine cell implantation in Parkinson's disease: Long-term clinical and (18)F-FDOPA PET outcomes. Journal of Nuclear Medicine 2010, 51:7-15.
42. Mendez I., Dagher A., Hong M., Gaudet P., Weerasinghe S., McAlister V., et al. Simultaneous intrastriatal and intranigral fetal dopaminergic grafts in patients with Parkinson disease: A pilot study. Report of three cases. Journal of Neurosurgery 2002, 96:589-596.
43. Mendez I., Dagher A., Hong M., Hebb A., Gaudet P., Law A., et al. Enhancement of survival of stored dopaminergic cells and promotion of graft survival by exposure of human fetal nigral tissue to glial cell line-derived neurotrophic factor in patients with Parkinson's disease. Report of two cases and technical considerations. Journal of Neurosurgery 2000, 92:863-869.
44. Mendez I., Viñuela A., Astradsson A., Mukhida K., Hallett P., Robertson H., et al. Dopamine neurons implanted into people with Parkinson's disease survive without pathology for 14 years. Nature Medicine 2008, 14:507-509.
45. Miletich R.S., Chan T., Gillespie M. Contralateral basal ganglia metabolism is abnormal in hemiparkinsonian patients. An FDG-PET study. Neurology 1988, 38:S260.
46. Morris E.D., Fisher R.E., Alpert N.M., Rauch S.L., Fischman A.J. In vivo imaging of neuromodulation using positron emission tomography: Optimal ligand characteristics and task length for detection of activation. Human Brain Mapping 1995, 3:35-55.
47. Morrish P.K., Rakshi J.S., Bailey D.L., Sawle G.V., Brooks D.J. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. Journal of Neurology, Neurosurgery and Psychiatry 1998, 64:314-319.
48. Morrish P.K., Sawle G.V., Brooks D.J. An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease. Brain 1996, 119:585-591.
49. Muñoz A., Li Q., Gardoni F., Marcello E., Qin C., Carlsson T., et al. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain 2008, 131:3380-3394.
50. Olanow C.W., Goetz C.G., Kordower J.H., Stoessl A.J., Sossi V., Brin M.F., et al. Annals of Neurology 2003, 54:403-414.
51. Pate B.D., Kawamata T., Yamada T., McGeer E.G., Hewitt K.A., Snow B.J., et al. Correlation of striatal fluorodopa uptake in the MPTP monkey with dopaminergic indices. Annals of Neurology 1993, 34:331-338.
52. Peschanski M., Defer G., N'Guyen J.P., Ricolfi F., Monfort J.C., Remy P., et al. Bilateral motor improvement and alteration of L-dopa effect in two patients with Parkinson's disease following intrastriatal transplantation of foetal ventral mesencephalon. Brain 1994, 117:487-499.
53. Piccini P., Brooks D.J., Björklund A., Gunn R.N., Grasby P.M., Rimoldi O., et al. Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nature Neuroscience 1999, 2:1137-1140.
54. Piccini P., Lindvall O., Björklund A., Brundin P., Hagell P., Ceravolo R., et al. Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Annals of Neurology 2000, 48:689-695.
55. Piccini P., Pavese N., Brooks D.J. Endogenous dopamine release after pharmacological challenges in Parkinson's disease. Annals of Neurology 2003, 53:647-653.
56. Piccini P., Pavese N., Hagell P., Reimer J., Björklund A., Oertel W.H., et al. Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain 2005, 128:2977-2986.
57. Playford E.D., Brooks D.J. In vivo and in vitro studies of the dopaminergic system in movement disorders. Cerebrovascular and Brain Metabolism Reviews 1992, 4:144-171.
58. Playford E.D., Jenkins I.H., Passingham R.E., Nutt J., Frackowiak R.S., Brooks D.J. Impaired mesial frontal and putamen activation in Parkinson's disease: A positron emission tomography study. Annals of Neurology 1992, 32:151-161.
59. Politis M., Wu K., Loane C., Quinn N.P., Brooks D.J., Rehncrona S., Bjorklund A., Lindvall O., Piccini P. Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Science Translational Medicine 2010, 2:38-46.
60. Rascol O., Sabatini U., Chollet F., Fabre N., Senard J.M., Montastruc J.L., et al. Normal activation of the supplementary motor area in patients with Parkinson's disease undergoing long-term treatment with levodopa. Journal of Neurology, Neurosurgery and Psychiatry 1994, 57:567-571.
61. Remy P., Samson Y., Hantraye P., Fontaine A., Defer G., Mangin J.F., et al. Clinical correlates of [18F]fluorodopa uptake in five grafted parkinsonian patients. Annals of Neurology 1995, 38:580-588.
62. Rinne J.O., Laihinen A., Rinne U.K., Någren K., Bergman J., Ruotsalainen U. PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson's disease. Movement Disorder 1993, 8:134-138.
63. Sawle G.V., Bloomfield P.M., Björklund A., Brooks D.J., Brundin P., Leenders K.L., et al. Transplantation of fetal dopamine neurons in Parkinson's disease: PET [18F]6-L-fluorodopa studies in two patients with putaminal implants. Annals of Neurology 1992, 31:166-173.
64. Smith S.M., Fox P.T., Miller K.L., Glahn D.C., Fox P.M., Mackay C.E., et al. Correspondence of the brain's functional architecture during activation and rest. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:13040-13045.
65. Snow B.J., Tooyama I., McGeer E.G., Yamada T., Calne D.B., Takahashi H., et al. Human positron emission tomographic [18F]fluorodopa studies correlate with dopamine cell counts and levels. Annals of Neurology 1993, 34:324-330.
66. Sullivan A.M., Pohl J., Blunt S.B. Growth/differentiation factor 5 and glial cell line-derived neurotrophic factor enhance survival and function of dopaminergic grafts in a rat model of Parkinson's disease. European Journal of Neuroscience 1998, 10:3681-3688.
67. Vingerhoets F.J., Schulzer M., Calne D.B., Snow B.J. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion?. Annals of Neurology 1997, 41:58-64.
68. Volkow N.D., Wang G.J., Fowler J.S., Logan J., Schlyer D., Hitzemann R., et al. Imaging endogenous dopamine competition with [11C]raclopride in the human brain. Synapse 1994, 16:255-262.
69. Wenning G.K., Odin P., Morrish P., Rehncrona S., Widner H., Brundin P., et al. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Annals of Neurology 1997, 42:95-107.
70. Widner H., Tetrud J., Rehncrona S., Snow B., Brundin P., Gustavii B., et al. Bilateral fetal mesencephalic grafting in two patients with parkinsonism induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). New England Journal of Medicine 1992, 327:1556-1563.
71. Wolfson L.I., Leenders K.L., Brown L.L., Jones T. Alterations of regional cerebral blood flow and oxygen metabolism in Parkinson's disease. Neurology 1985, 35:1399-1405.